Drug intelligence / Profile preview

4HF-08

Development stage: Preclinical
Lead developer: 4HF Biotec
Modality: Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

4HF-08 is an experimental small molecule drug conjugate (SMDC) currently in the discovery phase of development by 4HF Biotec for the treatment of colon cancer. Utilizing the company's AI-driven platform for target identification, 4HF-08 is designed to selectively deliver a therapeutic payload to cancer cells, potentially reducing systemic toxicity compared to traditional chemotherapy. The candidate is currently undergoing in silico and medicinal chemistry optimization to refine its targeting and pharmacological properties. As an SMDC, it typically consists of a targeting ligand, a linker, and a functional payload, aimed at improving the therapeutic index of chemotherapy by selectively delivering the drug to tumor cells.

Beyond the preview

Go deeper on 4HF-08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4HF-08.

Explore the full profile